###### Strengths and limitations of this study

-   One of the strengths of our study was the large sample size. To the best of our knowledge, this is one of the few studies done in Asia which looked at the trend of soluble FMS-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) in normal pregnancies.

-   This was a prospective cohort study which recruited women at our low-risk obstetrics clinic. Thus, our results would be relevant to the low-risk obstetrics population.

-   However, the number of subjects in some ethnic groups was small in our study, which may affect the precision of our finding.

-   Our study collected the blood samples at different gestational weeks, which might have had an impact on the timing of the peak of sFlt-1 or the drop in PlGF.

-   Finally, the observed differences among ethnic groups might be due to uncontrolled confounders rather than genetic variation. Thus, interpretation of our finding needs caution.

Introduction {#s1}
============

Pre-eclampsia is one of the leading causes of maternal and foetal morbidity and mortality and is estimated to occur in about 4% of pregnancies worldwide.[@R1] Pre-eclampsia is a multi-systemic disease and the exact pathophysiology is still unclear. Numerous studies indicate that the imbalance between placental pro-angiogenic and antiangiogenic vasoactive agents, such as placental growth factor (PlGF) and soluble FMS-like tyrosine kinase 1 (sFlt-1), respectively, contributes to the pathogenesis of pre-eclampsia.[@R2]

PlGF is a member of the vascular endothelial growth factor (VEGF) family which is primarily synthesised in the placenta[@R4] and binds to the VEGRF-1 receptor, resulting in angiogenic activity. sFlt-1 is a natural antagonist to VEGF and PlGF by binding to them and preventing them from interacting with their receptors, resulting in anti-angiogenic activity and systemic endothelial dysfunction. Multiple studies have found that gestational changes in sFlt-1 and PlGF correlate with the onset and severity of pre-eclampsia[@R3] and the sFlt-1/PlGF ratio has been investigated as a predictive biomarker for pre-eclampsia.[@R5]

It would be essential to know the trend of plasma sFlt-1 and PlGF biomarkers in normal pregnancies and the normal reference values so as to be able to validate the use of cutoffs of sFlt-1, PlGF and the sFlt-1/PlGF ratio for the prediction of pre-eclampsia. Interestingly, there are few longitudinal studies done to investigate these biomarkers in normal pregnancies[@R8] and most of these studies are conducted in non-Asian countries with a mainly Caucasian population. In view of the lack of data among the Asian population, our study aims to analyse the sFlt-1 and PlGF trends in the normal pregnant Asian women in Singapore.

Methods {#s2}
=======

Patient and public involvement {#s2a}
------------------------------

The participants could obtain the study results from the clinical coordinators. Patients and the public were not involved in the design or planning of the study.

Participants {#s2b}
------------

This study is a part of the Neonatal and Obstetrics Risks Assessment (NORA) prospective cohort study, which focused on evaluating the use of clinical, biochemical and biophysical markers to predict a risk of adverse pregnancy outcomes, including pre-eclampsia so that early clinical intervention can be implemented. NORA was conducted in KK Women's and Children's Hospital (KKH), the largest tertiary maternity hospital in Singapore that manages the largest number of complicated pregnancies locally. Women who had viable, singleton pregnancies and were attending their first antenatal visit, at less than 14+0 weeks of gestation, were screened for eligibility for the study in KKH between September 2010 and November 2013. The exclusion criteria were multiple gestations, chronic medical conditions such as renal disease or systemic lupus erythematosus and pregnancies complicated by aneuploidy or foetal anomaly. Written informed consent was obtained from each participant. The women recruited consisted of four different ethnicities; Chinese, Malay, Indian and others.

A total of 3271 women were screened and only 2820 women were eligible and out of which, 1013 women consented to participate in the study. Out of the 1013 participants, 934 (92.2%) patients completed all four antenatal visits. As eight participants did not deliver in our institution, we studied the outcomes of the remaining 926 (99.0%) patients ([figure 1](#F1){ref-type="fig"}).

![Neonatal and Obstetrics Risks Assessment study recruitment.](bmjopen-2018-028321f01){#F1}

Of the 926 women, there were 241 (26.0%) women with adverse pregnancy outcomes who were excluded from the current analysis. These adverse pregnancy outcomes, which were not mutually exclusive, consisted of 62 (6.7%) preterm births defined as gestational age (GA) \<37+0 weeks, 20 (2.2%) pre-eclampsia, 8 (0.9%) gestational hypertension, 102 (11.0%) intrauterine growth restriction (IUGR), defined as estimated foetal weight or abdominal circumference less than the fifth percentile adjusting for gender and ethnicity, or birth weight less than the third percentile, and 95 (10.3%) gestational diabetes mellitus. Of the 685 (74.0%) women with normal pregnancy outcomes, we further excluded those with pre-existing hypertension or diabetes, which may affect the sFlt-1 and PlGF values. Hence, we analysed the sFlt-1 and PlGF trends in the remaining 674 (72.8%) women with normal pregnancy outcomes.

The women were closely followed up throughout their pregnancies and clinical and laboratory data were collected prospectively. On recruitment at 11--14 weeks (V1), an interview and a dating ultrasound scan were completed, and blood samples were collected. Subsequently, the women were seen at 18--22 weeks, 28--32 weeks and 34 weeks and above. The remaining visits were defined as V2, V3 and V4, respectively. The women had routine ultrasound investigations at 18--22 weeks for screening of foetal anomalies and at 28--32 weeks for growth of the fetus. In addition, Doppler studies on umbilical, fetal middle cerebral and uterine arteries were performed at 18--22 weeks, 28--32 weeks and 34 weeks and above for detection of IUGR. Following delivery, data collection included the details and mode of delivery and neonatal outcomes.

Sample collection and assays {#s2c}
----------------------------

Serum levels of sFlt-1 and PlGF were measured at all study visits. For the serum samples, 5--10 mL venous blood was collected in non-heparinised tubes (serum) and assayed using the Elecsys 2010 and Cobas e411 electrochemiluminescence immunoassay machine. The detection limits were approximately 6 pg/mL for sFlt-1 and \<2 pg/mL for PlGF.

Statistical analysis {#s2d}
--------------------

The serum biomarkers---sFlt-1 and PlGF---and the sFlt-1/PlGF ratio at each visit were compared among the four ethnic groups using Kruskal Wallis test followed by post-hoc analysis of pairwise tests adjusted for multiple testing. One-sample t-test method was used to check whether change in sFlt-1 over the last two visits was significant. We performed the one-way analysis of variance analysis to investigate the trend of PlGF over the first three visits. Statistical analysis was performed using SAS V.9.4 for Windows. Statistical significance was set at p\<0.05. We adjusted the difference in biomarkers for possible confounders, which are parity, body mass index (BMI) and estimated foetal weight at visits V1--V3.

Results {#s3}
=======

The demographics of the population are described in [table 1](#T1){ref-type="table"}. The mean age was 30.5 (±1.0) years old and half of the patients (53.1%) were primiparous. The mean BMI at booking was 23.8 (±4.4) kg/m^2^ and the mean GA at booking was 39.0 (±1.0) weeks' of gestation. In terms of ethnicity, half of them were Chinese participants (51.0%) while 29.7% were Malay participants, 11.0% were Indian participants and the remaining 8.3% were of other ethnicity such as Eurasians.

###### 

Characteristics of the study cohort

  Demographics                           N     Mean±SD/%
  -------------------------------------- ----- -------------
   Age (years)                           674   30.5±1.0
  Ethinicity                                   
   Chinese                               344   51.0
   Malay                                 200   29.7
   Indian                                74    11.0
   Other                                 56    8.3
  Parity (excluding current pregnancy)         
   Nullip                                358   53.1
   Para 1                                217   32.2
   Para 2 and above                      99    14.7
   BMI at booking (kg/m^2^)              674   23.8±4.4
   GA at delivery (weeks)                674   39.0±1.0
   Birth weight at delivery (grams)      674   3213.2±0.34

The changes in sFlt-1 and PlGF in pregnancy are shown in [figures 2 and 3](#F2 F3){ref-type="fig"}, classified based on ethnicity. The mean and median values of the plasma biomarkers at each visit are shown in [table 2](#T2){ref-type="table"}. For sFlt-1, the plasma levels remained relatively constant until about 28--32 weeks of gestation and increased significantly in the third trimester (p\<0.001) across all four ethnic groups. The overall median values (10th−90th percentile) of sFlt-1 at V1, V2, V3 and V4 were 1600 pg/mL (996.2--2666), 1752.0 pg/mL (941.7--3259.0), 1690.5 pg/mL (941.2--2984.5) and 2640.0 pg/mL (1550.0--4820.0), respectively. The sFlt-1 levels started to rise significantly before 30 weeks' of gestation among the Malay participants and the other ethnicities as compared with the Chinese and Indian participants whose levels only increased after 30 weeks' of gestation ([figure 2](#F2){ref-type="fig"}). There were no significant differences in the sFlt-1 values between the different ethnicities at each of the visits ([table 2](#T2){ref-type="table"}).

###### 

Soluble FMS-like tyrosine kinase-1 (sFlt-1), placental growth factor (PlGF) and sFlt-1/PlGF ratios at each of the visits and the differences between each visit

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable   Visit                     Chinese participants          Malay participants             Indian participants           Other ethnicities participants   P value                                            
  ---------- ------------------------- ----------------------------- ------------------------------ ----------------------------- -------------------------------- --------- ----------------- ---- ----------------- --------------
  SFlT1      V1                        341                           1791.3±721.49/\                199                           1689.9±626.91/\                  74        1666.24±905.73/   56   1801.45±812.11/   0.293
                                                                     1616(1295--2153)                                             1592(1241--2040)                                                                    

             1430(1128--1993)          1668.5(1150.5--2261.5)                                                                                                                                                         

             V2                        340                           1998.39±1097.05/\              199                           2046.34±1114.17/                 74        1754.87±830.37/   56   2011.45±970.36/   0.2424
                                                                     1782(1265.5--2377)                                                                                                                               

             1758(1292--2499)          1650(1208--2058)              1810(1296--2524)                                                                                                                                 

             V3                        331                           1967.85±1190.31/\              190                           1908.55±1007.28/                 74        1793.46±774.06/   55   1791.37±669.24/   0.4676
                                                                     1727(1255--2264)                                                                                                                                 

             1672.5(1300--2355)        1650.5(1287--2025)            1675(1367--2158)                                                                                                                                 

             V4                        296                           3171.11±1930.8/                166                           3113.97±1662.73/                 64        2879.43±1576.4/   51   2637.59±869.31/   0.175

             2674.5(2033.5--3691.5)    2672(2029--3725)              2611(1749--3356)               2449(1879--3279)                                                                                                  

             V2−V1\*                   160.74 **(72.21, 249.27)**    315.44 **(201.35, 429.52)**    127.63 (−49.74, 305.00)       168.70 **(−26.93, 364.34)**      --                                                 

             V3−V2\*                   −39.95 (−144.1, 64.16)        −190.8 **(-−325.0,--56.61)**   84.45 (−124.2, 293.05)        −272.3 **(-502.3,--42.18)**      \-                                                 

             V4−V3\*                   821.99 **(634.54, 1009.4)**   657.10 **(415.52, 898.67)**    787.53 **(411.96, 1163.1)**   685.65 **(271.39, 1099.9)**      \-                                                 

  PlGF       V1                        341                           44.65±116.26/\                 199                           43.09±27.54/                     74        51.69±37.61/      56   50.93±58.72/      0.8547
                                                                     33.51 (25.02--46.37)                                                                                                                             

             35.11 (24.85--55.02)      42.51 (28.93--62.17)          35.51 (26.02--52.55)                                                                                                                             

             V2                        340                           283.83±148.08/\                199                           297.14±155.24/                   74        342.24±164.32/    56   319.27±190.32/    **0.021**
                                                                     249.35 (186.6--347)                                                                                                                              

             261.9 (201.7--347.6)      316.55 (238.2--401.8)         282.95 (194.9--364.75)                                                                                                                           

             V3                        331                           662.97±450.77/\                190                           754.75±424.07/                   74        1002.08±611.96/   55   884.09±546.42/    **\<**0.0001
                                                                     548.7 (356.5--847.7)                                                                                                                             

             674.65 (446--950.9)       880.1 (546--1315)             761.7 (506.5--1214)                                                                                                                              

             V4                        296                           472.45±655.88/                 166                           512.23±484.85/                   64        674.11±479.76/    51   695.44±567.02/    **0.0126**

             311.45 (178.75--563.25)   384.9 (202.9--664.1)          570.45 (278.35--909.5)         531.3 (319.3--877.5)                                                                                              

             V2−V1\*                   228.90 **(212.60, 245.19)**   258.03 **(237.03, 279.03)**    280.36 **(247.71, 313.01)**   277.91 **(241.90, 313.92)**      \-                                                 

             V3-−V2\*                  356.03 **(314.94, 397.13)**   450.97 **(398.01, 503.93)**    619.98 **(537.64, 702.31)**   484.03 **(393.21, 574.85)**      \-                                                 

             V4−V3\*                   −217.9 **(−276.5,--159.4)**   −288.3 **(−363.7,--212.8)**    −409.8 **(−527.2,--292.5)**   −195.7 **(−325.1,--66.25)**      \-                                                 

  Ratio†     V1                        341                           54.49±27.19/\                  199                           49.28±26.42/                     74        39.71±22.11/      56   48.34±23.06/      **0.0001**
                                                                     49.9 (35.87--68.85)                                                                                                                              

             44.56 (30.57--62.91)      35.4 (24.77--49.14)           48.97 (27.58--58.23)                                                                                                                             

             V2                        340                           8.46±6.9/                      199                           7.89±4.4/                        74        6.14±4.23/        56   8.36±7.18/        **0.0259**

             6.97 (4.76--10.31)        7.1 (4.65--9.78)              5.08 (3.27--7.03)              7.11 (4.47--10.31)                                                                                                

             V3                        331                           5.72±13.53/                    190                           3.79±5.62/                       74        3.67±6.75/        55   3.22±3.45/        0.0933

             3.03 (1.83--4.88)         2.55 (1.54--4.1)              1.83 (1.2--2.81)               2.15 (1.34--4.12)                                                                                                 

             V4                        296                           16.43±26.83/                   166                           13.97±20.57/                     64        9.01±13/          51   9.06±11.34/       **0.0343**

             8.94 (3.95--17.21)        8.33 (2.88--15.41)            4.43 (2.35--10.39)             4.55 (2.47--10.79)                                                                                                

             V2−V1\*                   −44.83 **(−47.35,--42.30)**   −42.13 **(−45.39,--38.88)**    −34.90 **(−39.96,--29.84)**   −39.66 **(-−45.25,--34.08)**     \-                                                 

             V3−V2\*                   −2.20 **(−3.57,--0.82)**      −4.28 **(−6.05,--2.50)**       −2.01 (-4.77, 0.76)           −5.77 **(−8.81,--2.72)**         \-                                                 

             V4−V3\*                   7.93 **(−5.85, 10.00)**       7.13 **(−4.46, 9.80)**         6.81 **(2.66, 10.97)**        5.14 **(−0.56, 9.72)**           \-                                                 
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Denotes the difference in values between the visits, respectively, (Lease Square (LS) Means and 95% CI). They are adjusted for confounders: parity, BMI and estimated foetal weight at visits V1--V3.

†Ratio refers to the sFlt-1/PlGF ratio.

Bold values signifies that the 95 % confidence interval which do not cross 1.
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![Placental growth factor trend across gestational age.](bmjopen-2018-028321f03){#F3}

For PlGF, the levels increased from the first to the third trimester, peaking at 30--32 weeks before decreasing (p\<0.001). The overall median values (10th--90th percentile) of PlGF at V1, V2, V3 and V4 were 34.7 pg/mL (20.3--70.3), 263.0 pg/mL (148.8--474.4), 636.4 pg/mL (257.2--1405.5) and 369.9 pg/mL (130.1--1077.0), respectively. The PlGF levels dropped at a later gestation among the Malay and other ethnicities participants as compared with the Chinese and Indian participants whose levels peaked at 30 weeks. There were significant differences in the PlGF values between the different ethnicities where the values are significantly higher among the Indian and other ethnicities participants as compared with the Malay and Chinese participants at V3 and V4, p=0.04 and p\<0.001, respectively) ([table 2](#T2){ref-type="table"}).

The sFlt-1/PlGF ratios are shown in [table 2](#T2){ref-type="table"}. The ratios reflected a decrease from V1 to V3 and increases between V3 and V4 ([figure 4](#F4){ref-type="fig"}). The values were also significantly different among the four ethnic groups at V1, V2 and V4.

![Ratio trend across gestational age.](bmjopen-2018-028321f04){#F4}

Discussion {#s4}
==========

Main findings {#s4a}
-------------

This study describes the changes in sFlt-1 and PlGF levels throughout pregnancy in an Asian population with normal outcomes in Singapore and provides the references ranges for the 10th^--^90th percentiles. From the longitudinal studies done in other countries,[@R6] the sFlt-1 level is almost ten times that of a non-pregnant woman and stays constant until the last 2 months of pregnancy when it increases. Our results were consistent with the other studies as it showed that sFlt-1 remained relatively stable till GA 28--32 weeks before it started to rise. Interestingly, there was a significant difference in the rise of sFlt-1 levels among the four ethnic groups. Since the sFlt-1 levels rise before 30+0 weeks of gestation among the Malay and other ethnicities participants, it would be important to correct for ethnicity when using these reference values to obtain a cut-off for prediction of preeclampsia. Wolf *et al* investigated the difference in levels of sFlt-1 between a woman's first and second pregnancies and found that Hispanic women had higher levels than white women in the first pregnancy but lower levels in the subsequent pregnancies.[@R15] Hence, there could be a genetic component that affects the sFlt-1 level.

For PlGF, its plasma level is about twice that of a non-pregnant woman in the first trimester and increases up to 32--34 weeks before decreasing in the last 2 months of pregnancy.[@R6] Our results on PlGF trend were also consistent with what has been observed where PlGF increases steadily to a peak at about 30--32 weeks before decreasing. There were significant differences in values among the four ethnic groups at V2, V3 and V4 (p\<0.001) where the Chinese and Malay participants have significantly lower values than the Indian and other ethnicities participants. This has been reflected in other studies which showed that PlGF values differ between the various ethnic groups.[@R15]

Strengths and limitations {#s4b}
-------------------------

One of the strengths of our study was the large sample size. To the best of our knowledge, this is one of the few studies done in Asia which looked at the trend of sFlt-1 and PlGF in normal pregnancies. In addition, this was a prospective cohort study which recruited women at our low-risk obstetrics clinic. Thus, our results would be relevant to the low-risk obstetrics population. However, the number of subjects in some ethnic groups was small in our study, which may affect the precision of our finding. Also, our study collected blood samples at different GA windows, and the timing of specimen collection might have had an impact on the timing of the peak of sFlt-1 or the drop in PlGF. Finally, the observed differences among ethnic groups might be due to uncontrolled confounders rather than genetic variation. Thus, interpretation of our finding needs caution.

Interpretation {#s4c}
--------------

The changes in sFlt-1 and PlGF during pregnancy found in our study were consistent with that in other populations. We can also use these values in our local population to investigate their role in predicting pre-eclampsia and other possible complications such as IUGR.

Conclusion {#s5}
==========

The trends in PlGF and sFlt-1 concentrations over gestation in Asian women in Singapore are consistent with the findings in other studies. As there are significant differences in the biomarkers between different ethnicity, ethnicity should be an important factor in the analysis of these biomarkers. Further research would encompass using these reference values to compare with women who developed pre-eclampsia and obtaining a predictive cut-off ratio for the risk of pre-eclampsia.
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